Infective endocarditis - A review of current therapy and future challenges.


Journal

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
ISSN: 2241-5955
Titre abrégé: Hellenic J Cardiol
Pays: Netherlands
ID NLM: 101257381

Informations de publication

Date de publication:
Historique:
received: 31 07 2020
revised: 30 08 2020
accepted: 12 10 2020
pubmed: 12 11 2020
medline: 19 8 2021
entrez: 11 11 2020
Statut: ppublish

Résumé

Etiological, microbiological and epidemiological factors changed over time, but mortality rates remain high in infective endocarditis (IE). Healthcare-associated IE is nowadays responsible for a significant proportion of cases due to increasing numbers of cardiac devices. Cardiac implantable electronic devices, transcatheter aortic valve replacement, and percutaneous valve repair are meanwhile used, especially in old and sick patients. In suspected IE modified Duke criteria, integrating clinical results, imaging, and biomarkers are traditionally applied. Newer imaging technologies such as multi-slice computed tomography, photon-emission computed tomography, and magnetic resonance imaging might add value to conventional echocardiography in diagnosis and management of IE. Treatment consists of long-term antibiotic therapy, infectiological source control and/or cardiac surgery. Recently, antibiotic parenteral outpatient regimens and partial oral treatment strategies were shown to shorten hospital stays in patients suffering from IE. However, it remains unclear how to best select patients for partial oral therapy. This review describes new trends in diagnosing, imaging, and treating IE in a changing patient collective with particular focus on patients with implantable cardiac devices.

Identifiants

pubmed: 33176209
pii: S1109-9666(20)30248-7
doi: 10.1016/j.hjc.2020.10.007
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

190-200

Informations de copyright

Copyright © 2020 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.

Auteurs

Richard Rezar (R)

Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: r.rezar@salk.at.

Michael Lichtenauer (M)

Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: m.lichtenauer@salk.at.

Markus Haar (M)

Department of Cardiology, Paracelsus Medical University of Nuremberg, Germany. Electronic address: markus.haar@klinikum-nuernberg.de.

Georg Hödl (G)

Institute of Radiology, Academic Teaching Hospital Wels-Grieskirchen, Austria. Electronic address: georg.hoedl@klinikum-wegr.at.

Jan Marco Kern (JM)

Division of Medical Microbiology, Department of Laboratory Medicine, Paracelsus Medical University of Salzburg, Austria. Electronic address: j.kern@salk.at.

Zhichao Zhou (Z)

Department of Medicine, Division of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. Electronic address: zhichao.zhou@ki.se.

Thomas Wuppinger (T)

Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: th.wuppinger@salk.at.

Johannes Kraus (J)

Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: j.kraus@salk.at.

Bernhard Strohmer (B)

Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: b.strohmer@salk.at.

Uta C Hoppe (UC)

Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: u.hoppe@salk.at.

Bernhard Wernly (B)

Clinic of Internal Medicine II, Department of Cardiology, Paracelsus Medical University of Salzburg, Austria. Electronic address: bernhard@wernly.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH